Collegium Pharmaceutical, Inc.
COLL
$28.23
$0.080.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.31% | 19.88% | 23.62% | 26.34% | 22.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.31% | 19.88% | 23.62% | 26.34% | 22.61% |
| Cost of Revenue | -3.43% | 0.21% | 4.07% | 12.07% | 11.22% |
| Gross Profit | 16.85% | 22.81% | 26.60% | 28.53% | 24.42% |
| SG&A Expenses | 29.27% | 33.96% | 53.75% | 73.79% | 66.00% |
| Depreciation & Amortization | 10.69% | 19.13% | 34.23% | 53.72% | 48.16% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.92% | 22.39% | 36.67% | 53.27% | 47.49% |
| Operating Income | 5.53% | 12.83% | -4.62% | -20.86% | -21.87% |
| Income Before Tax | 46.58% | 66.34% | -6.04% | -36.84% | -62.47% |
| Income Tax Expenses | 77.97% | 57.21% | 1.26% | -43.15% | -59.52% |
| Earnings from Continuing Operations | 32.10% | 70.75% | -9.13% | -34.03% | -63.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.10% | 70.75% | -9.13% | -34.03% | -63.69% |
| EBIT | 5.53% | 12.83% | -4.62% | -20.86% | -21.87% |
| EBITDA | 8.34% | 15.77% | 12.93% | 8.93% | 6.47% |
| EPS Basic | 34.35% | 73.62% | -7.25% | -32.79% | -63.00% |
| Normalized Basic EPS | 21.61% | 23.70% | -12.76% | -40.14% | -40.32% |
| EPS Diluted | -15.49% | 38.92% | -7.27% | -33.62% | -61.44% |
| Normalized Diluted EPS | 17.07% | 21.78% | -11.66% | -38.55% | -38.46% |
| Average Basic Shares Outstanding | -0.13% | -1.12% | -1.76% | -1.60% | -2.19% |
| Average Diluted Shares Outstanding | -0.10% | 3.36% | -6.58% | -7.23% | -7.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |